Search
Armodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. … Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep
Secobarbital
go.drugbank.com/drugs/DB00418ApprovedVet approvedSecobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties.
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedPropythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism.
Naltrexone
go.drugbank.com/drugs/DB00704ApprovedInvestigationalVet approvedDerivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Cyclopropylmethylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydromorphinoneTixocortol
go.drugbank.com/drugs/DB09091ApprovedWithdrawnTixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...
Interferon alfa-2a
go.drugbank.com/drugs/DB00034ApprovedInvestigationalWithdrawnAn oral form is being developed by Amarillo Biosciences. … This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Products: ROFERON - A ROCHE SOLUCION INYECTABLE 3 K/U.I.Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigationalIt was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342] … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). … Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407].
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases.